In the ever-changing landscape of global M&A and deal-making, health and life sciences remain top priorities, offering both growth potential and defensive strategies. In these markets, understanding regulatory and policy shifts is crucial.
McDermott’s international health and life sciences team works with clients to anticipate the impact of changing regulatory, reimbursement and strategic issues on their deals. McDermott Will & Emery’s international Guide reveals insights on forthcoming legal and regulatory risk, changes to drug approvals and device certification, upcoming AI regulation, telemedicine, merger control and more. Read more.
